NCT04402879

Brief Summary

The purpose of this trial is to determine whether Prone Positioning (PP) improves outcomes for non-intubated hospitalized patients with hypoxemic respiratory failure due to COVID-19, who are not candidates for mechanical ventilation in the ICU. The investigators hypothesize that PP will reduce in-hospital mortality or discharge to hospice, compared with usual care for non-intubated patients with do-not-intubate goals of care with hypoxemic respiratory failure due to probable COVID-19.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
596

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 27, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

November 10, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

December 17, 2020

Status Verified

May 1, 2020

Enrollment Period

1.1 years

First QC Date

May 22, 2020

Last Update Submit

December 14, 2020

Conditions

Keywords

Prone positioningnon-intubated

Outcome Measures

Primary Outcomes (1)

  • Hospital mortality or discharge to hospice

    In-hospital mortality or discharge to hospice at Day 60.

    60 days

Secondary Outcomes (9)

  • Adverse Events and Serious Adverse Events

    60 days

  • Change in SpO2

    60 days

  • Hospital free days

    60 days

  • Admission to ICU

    60 days

  • Intubation and mechanical ventilation

    60 days

  • +4 more secondary outcomes

Study Arms (2)

Prone Positioning (PP)

EXPERIMENTAL

The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.

Procedure: Prone Positioning (PP)

Control - usual management

NO INTERVENTION

The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.

Interventions

The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge. The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements.

Prone Positioning (PP)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hospitalized patients with probable COVID-19. Probable is defined as Influenza like illness (ILI) symptoms OR confirmed COVID-19 exposure AND COVID-19 testing performed. ILI is defined as any one of the following symptoms including: fever, new or worsening cough, coryza, new or worsening dyspnea, or sore throat.
  • Goals of care are do-not-intubate (R3 or M1/M2 in Alberta).
  • Need for oxygen ≥2 L to maintain SpO2 ≥92%. If the patient is on long-term oxygen, the O2 requirements must be ≥2 L above their baseline.
  • Patient can be positioned to and from prone to supine with minimal assistance (maximum one person assistance).

You may not qualify if:

  • Decreased level of consciousness (Glasgow Coma Scale \< 10) or precluding ability to self-reposition.
  • Hemodynamic instability (Systolic Blood Pressure \< 90 mmHg and or Lactate \>5 mmol/L or HR \>120, not responsive to fluid resuscitation).
  • Complete bowel obstruction.
  • Active upper gastrointestinal bleeding.
  • Poor neck mobility or patient inability to lie prone comfortably.
  • Unstable spine, femur, or pelvic fractures.
  • Pregnancy - third trimester.
  • Full resuscitation status including ICU and willingness to accept invasive mechanical ventilation (i.e. R1/R2 goals of care).
  • Imminent palliation or end of life expected on admission (i.e. C1/C2 goals of care).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Peter Lougheed Centre (PLC)

Calgary, Alberta, T1Y 6J4, Canada

RECRUITING

Foothills Hospital Intensive Care Unit

Calgary, Alberta, T2N 2T9, Canada

RECRUITING

Rockyview General Hospital

Calgary, Alberta, T2V 1P9, Canada

NOT YET RECRUITING

South Health Campus

Calgary, Alberta, T3M 1M4, Canada

NOT YET RECRUITING

Related Publications (1)

  • Weatherald J, Norrie J, Parhar KKS. Awake prone positioning in COVID-19: is tummy time ready for prime time? Lancet Respir Med. 2021 Dec;9(12):1347-1349. doi: 10.1016/S2213-2600(21)00368-4. Epub 2021 Aug 20. No abstract available.

MeSH Terms

Conditions

COVID-19Respiratory Distress SyndromeRespiratory Insufficiency

Interventions

Prone Position

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesRespiration Disorders

Intervention Hierarchy (Ancestors)

PostureMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Ken Parhar, MD, MSc

    University of Calgary

    PRINCIPAL INVESTIGATOR
  • Jason Weatherald, MD

    University of Calgary

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ken Parhar, MD, MSc

CONTACT

Jason Weatherald, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a prospective, unblinded, randomized controlled trial at four (4) medical sites in Calgary, Alberta.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant Intensivist & Clinical Assistant Professor

Study Record Dates

First Submitted

May 22, 2020

First Posted

May 27, 2020

Study Start

November 10, 2020

Primary Completion

December 1, 2021

Study Completion

June 1, 2022

Last Updated

December 17, 2020

Record last verified: 2020-05

Locations